

LE GINECO A L'ASCO 2020 !

GYNECOLOGICAL ORAL SESSION		
DESKTOP III – Overall Survival		Abstract # 6000
SOLO 2 – Overall Survival		Abstract # 6002
GYNECOLOGICAL POSTER DISCUSSION		
SOLO2 CA125 progression recist		Abstract # 6014
TMRG – Small cell carcinoma		Abstract # 6023
GYNECOLOGICAL POSTER		
SOLO2	Age dependency	Abstract # 6068
SOLO2	Subsequent therapies	Abstract # 6070
PAOLA-1	Efficacy by BRCA1/BRCA2	Abstract # 6039
PRIMA	Evaluation of individualized starting dose	Abstract # 6050
<u>Study in Progress</u> : UTOLA, FIRST		
CLINICAL SCIENCE SYMPOSIUM OVARIAN ORAL SESSION		
CHIVA	Immune tumor microenvironment	Abstract # 6011
CLINICAL SCIENCE SYMPOSIUM BREAST ORAL SESSION		
PADA1	Exploratory analysis	Abstract # 1010

ORAL PRESENTATION : GYNECOLOGICAL CANCER

DESKTOP III **Andreas du Bois – Abstract #6000**

Randomized phase iii study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer. Final analysis of AGO DESKTOPIII/ENGOT-ov20.

SOLO2 **Andres Poveda – Abstract #6002**

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation

POSTER DISCUSSION : GYNECOLOGICAL CANCER

SOLO2 **Angelina Tjokrowidjaja - Abstract #6014**

Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.

TMRG **Félix Blanc - Abstract #6023**

Effect of high-dose chemotherapy with autologous stem cell rescue (HDC-aSCR) on outcome in ovarian small-cell carcinoma, hypercalcemic type (SCCOHT): Prospective series from the French Rare Gynecologic Malignant Tumors Network (TMRG).

POSTER : GYNECOLOGICAL CANCER

SOLO2 **Fabian Trillsch - Abstract #6068**

Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.

SOLO2 **J-Sébastien Frenel - Abstract #6070**

Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).

PAOLA-1 **K.Lorusso – Abstract #6039**

Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the Phase III PAOLA-1 trial

CLINICAL SCIENCE SYMPOSIUM OVARIAN ORAL SESSION

CHIVA **Alexandra Leary – Abstract #6011**

Impact of chemotherapy alone or in combination with an anti-angiogenic on the immune tumor microenvironment (TME) of ovarian cancer: Data from the randomized CHIVA trial (a GINECO – GINEGEPS study).

CLINICAL SCIENCE SYMPOSIUM BREAST ORAL SESSION

PADA-1 **François Clément Bidart – Abstract #1010**

Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial